TRIM8 and colorectal carcinoma: By restoring normal TRIM8 levels, CRC cells recover sensitivity to chemotherapy treatments such as Sorafenib, Axitinib, which are among the Tyrosine Kinase inhibitors currently in use for treatment of both renal and colorectal carcinoma [257,258,259,260], and also to Nutlin-3 and Cisplatin [150].